SPRO Spero Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1701108 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.5%
TTM net income YoY32.7%
TTM EPS YoY36.7%
Revenue 3-yr CAGR-18.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-67.3%
Net margin-71.0%
FCF margin—
EBITDA margin—
Returns
ROE-216.4%
ROA-35.9%
ROIC (approx.)—
Asset turnover0.51x
Leverage & solvency
Liabilities / assets99.3%
Debt / equity0.00x
Current ratio1.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio13.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY2022*2022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $66.80M | $47.98M | $103.78M | $53.51M | $18.26M |
| R&D expense | $38.47M | $96.76M | $51.44M | $47.59M | $64.53M |
| SG&A expense | $21.18M | $23.70M | $25.55M | $36.48M | $41.70M |
| Operating income | $6.31M | -$73.36M | $21.48M | -$42.20M | -$87.97M |
| Pretax income | $8.83M | -$68.57M | $25.40M | -$46.41M | -$89.76M |
| Income tax | $261,000 | $0 | $2.60M | $0 | $0 |
| Net income | $8.57M | -$68.57M | $22.81M | -$46.41M | -$89.80M |
| EBITDA | $6.31M | -$73.36M | $21.85M | -$41.33M | -$87.33M |
| EPS (basic) | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 |
| EPS (diluted) | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 |
| Weighted avg. shares (diluted) | 59.04M | 54.04M | 52.99M | 37.59M | 30.90M |
| Balance sheet | |||||
| Cash & equivalents | $40.27M | $52.89M | $76.33M | $109.11M | $112.58M |
| Short-term investments | — | — | — | $0 | $33.82M |
| Current assets | $67.29M | $107.28M | $131.21M | $113.57M | $157.87M |
| PP&E, net | — | $0 | $2,000 | $368,000 | $1.03M |
| Total assets | $68.92M | $110.54M | $182.39M | $124.80M | $171.07M |
| Current liabilities | $8.87M | $49.07M | $37.15M | $21.65M | $18.67M |
| Total liabilities | $9.90M | $64.42M | $75.50M | $48.87M | $82.78M |
| Shareholders' equity | $59.02M | $46.12M | $106.89M | $75.93M | $88.29M |
| Shares outstanding | 56.41M | 54.59M | 53.00M | 52.46M | 32.39M |
| Cash flow statement | |||||
| Operating cash flow | -$12.62M | -$23.44M | -$32.99M | -$7.73M | -$64.35M |
| Investing cash flow | — | — | $0 | $33.81M | $7.67M |
| Financing cash flow | — | $0 | $221,000 | -$29.55M | $84.05M |
| Depreciation & amortization | $0 | $2,000 | $367,000 | $869,000 | $646,000 |
| Stock-based compensation | $4.33M | $7.79M | $7.93M | $9.12M | $9.43M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.